New Bacterial Vaccines focuses upon unfulfilled needs for bacterial vaccines. The increase in drug resistance among many bacterial species has increased the need for new bacterial vaccines. This book serves as a comprehensive reference on the major aspects of developing new bacterial vaccines. The distinctive feature of this book is that it focuses upon new vaccines now under development by reviewing key issues for each vaccine target and new technologies being applied to developing new vaccines. This book should prove useful for students in the life sciences, scientists, developers of vaccines and biotechnology products, clinicians, regulators, and health-care practitioners.

The importance of vaccines to combat bacterial diseases cannot be overstated. Methods used in the development and testing of these vaccines are evolving rapidly as a direct consequence of the availability of advanced technologies. This volume will cover methods developed in the last decade, the usage of which are enabling the development of cheaper, cost-effective and structurally stable vaccines for global use. Chapters cover in silico analytical methods such as reverse vaccinology and machine learning; low-energy electron irradiation for the generation of inactivated bacterial vaccines; methods for assessment of OMV/GMMA quality and stability; and controlled human infection models. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Bacterial Vaccines: Methods and Protocols is a valuable resource for novice and expert researchers interested in learning more about this important and constantly evolving field.

It was not too long ago that many physicians and biomedical scientists felt that the era of 'vaccines' for protecting mankind against infectious disease was coming to an end. During the 1 940s and 50s the widespread use of newly developed antibiotics and antimicrobial chemotherapeutic agents suggested a new era in medicine, i. e. the control and eventual elimination of all infectious diseases, at least those caused by bacteria, by' chemical means. The magic 'bullet' proposed by Paul Ehrlich in the early 1900s seemed to be the method of choice for controling infection. However, it is now quite evident that those high expectations were unwarranted. Although many acute infections, especially those caused by pyogenic cocci, have been controlled by antibiotics, it is quite evident that infectious diseases, even those caused by bacteria, still are a major problem. Thus, the old 'standby' of preventative vaccination is making a strong comeback, not only for viral but also for bacterial infections. However, except for a relatively small number of viral diseases and those bacterial diseases due to toxin elaborated by microorganisms rather than invasion and replication of the microbe per se, preventative vaccination still has not fulfilled the expectations of their proponents. There has been a recent resurgence of interest concerning all aspects of vaccines, not only their preparation and administration, but also the nature and mechanism of the host immune response to the constituent micro organisms and their products.

This report surveys opportunities for future Army applications in biotechnology, including sensors, electronics and computers, materials, logistics, and medical therapeutics, by matching commercial trends and developments with enduring Army requirements. Several biotechnology areas are identified as important for the Army to exploit, either by direct funding of research or by indirect influence of commercial sources, to achieve significant gains in combat effectiveness before 2025.

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis. What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development. This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines: Lessons to be learned from the polio experience. Scientific advances that set the stage for new vaccines. Factors that affect how vaccines are used in the population. Value judgments and ethical questions raised by comparison of health needs and benefits. The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.